Type 2 diabetes mellitus
Conditions
Interventions
Oral vildagliptin administration (50 mg) twice daily.
Oral glimepiride administration (1-2 mg) once daily.
Sponsors
Nippon Medical School Department of Medicine Division of Cardiology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age more than 20 years 2) Outpatients 3) Inadequate glucose control even after dietary and exercise therapies for more than 8 weeks 4) No previous administration of pioglitazone as an oral hypoglycemic drug 5) 6.1% more than fasting HbA1c under 10% 6) Fasting blood glucose less than 270 mg/dl 7) Patients who themselves can voluntarily provide written consent to participate in this study, and can also follow the study protocol
Exclusion criteria
Exclusion criteria: 1) Type I diabetes mellitus 2) Patients receiving insulin therapy 3) Severe renal dysfunction requiring hemodialysis or peritoneal dialysis 4) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety 5) Patients who are deemed to be inappropriate by the investigator or sub-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow mediated dilation (FMD) | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, fasting blood glucose | — |
Countries
Japan
Contacts
Public ContactYoshiaki Kubota
Nippon Medical School Department of Medicine Division of Cardiology
Outcome results
None listed